ICH Consults On Supporting Multi-Regional Trials, Non-Clinical Evaluation Of Anticancer Drugs
Executive Summary
The International Council on Harmonisation has endorsed draft versions of two new guidelines – one on conducting multi-regional clinical trials and the other on supporting the non-clinical evaluation of anticancer medicines. The ICH is now seeking stakeholder feedback on both documents.
You may also be interested in...
New ICH Q&A To Support Uptake Of 'Vague' Safety Guideline For Anticancer Drugs
All parties that have used the ICH S9 guideline on the non-clinical evaluation of anticancer medicines have
Japan Builds Asia Links Through New AMED Programs
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
ICH: India, Mexico And Russia Among New Observers; Benefit-Risk Guideline Adopted
India, Mexico, Singapore, South Korea, Russia and Taiwan are among the latest countries to become observers at the International Council for Harmonisation, which has been seeking to establish itself as a 'truly global platform' since undergoing major structural reforms last year1.